Fabry disease (Anderson-Fabry disease) is an X-linked lysosomal storage disorder caused by deficiency of the enzyme alpha-galactosidase A (α-Gal A), leading to accumulation of globotriaosylceramide (Gb3/GL-3) in various tissues throughout the body[@germain2010]. The disease affects multiple organ systems including the kidneys, heart, nervous system, and skin. Treatment strategies for Fabry disease have evolved significantly over the past two decades, now encompassing disease-specific therapies, symptomatic management, and emerging approaches.
Fabry disease (Anderson-Fabry disease) is an X-linked lysosomal storage disorder caused by deficiency of the enzyme alpha-galactosidase A (α-Gal A), leading to accumulation of globotriaosylceramide (Gb3/GL-3) in various tissues throughout the body[@germain2010]. The disease affects multiple organ systems including the kidneys, heart, nervous system, and skin. Treatment strategies for Fabry disease have evolved significantly over the past two decades, now encompassing disease-specific therapies, symptomatic management, and emerging approaches.
Disease-Modifying Therapies
Enzyme Replacement Therapy (ERT)
Enzyme replacement therapy remains the cornerstone of Fabry disease treatment, providing exogenous α-Gal A to reduce substrate accumulation[@schiffmann2001].
Agalsidase Alfa (Replagal)
Manufacturer: Takeda (formerly Shire)
Dose: 0.2 mg/kg body weight every other week via intravenous infusion
Infusion time: Approximately 40 minutes
Efficacy: Demonstrated reduction in Gb3 accumulation in renal podocytes, endothelial cells, and myocardial cells; stabilization of renal function; reduction in cardiac mass; improvement in neuropathic pain and quality of life[@eng2006]
Immunogenicity: Approximately 50-70% of patients develop anti-drug antibodies, which may reduce efficacy in some patients
Agalsidase Beta (Fabrazyme)
Manufacturer: Sanofi Genzyme
Dose: 1 mg/kg body weight every other week via intravenous infusion
Infusion time: Approximately 1-2 hours
Efficacy: Similar to agalsidase alfa in reducing substrate burden and stabilizing organ function; approved for patients with confirmed Fabry disease[@fabrazyme]
Immunogenicity: Similar antibody development rates as agalsidase alfa
Comparative Considerations
Both ERT formulations have demonstrated similar clinical outcomes in head-to-head comparisons[@vedder2007]. The choice between formulations may depend on:
Payer coverage and reimbursement
Infusion tolerability
Antibody status
Patient preference for infusion duration
Pharmacological Chaperone Therapy
Migalastat (Galafold)
Manufacturer: Amicus Therapeutics
Mechanism: Oral small-molecule pharmacological chaperone that binds to and stabilizes mutant α-Gal A, facilitating proper folding and trafficking to lysosomes[@germain2019]
Dose: 123 mg every other day (on alternate days)
Eligibility: Patients with amenable GLA gene mutations (approximately 35-50% of all Fabry patients)
Efficacy: Demonstrated reduction in Gb3 in kidney interstitial capillaries; stabilization of renal function; reduction in cardiac mass; improvement in neuropathic pain[@hughes2017]
Advantages: Oral administration; no risk of infusion reactions; no immunogenicity concerns
Limitations: Only effective for patients with amenable mutations; requires genetic testing to confirm eligibility
Emerging Disease-Modifying Therapies
Gene Therapy
Gene therapy approaches for Fabry disease aim to deliver a functional GLA gene to restore endogenous α-Gal A production[@kohn2022]. Several clinical trials are ongoing:
AAV-mediated gene delivery: Early-phase trials showing promising results with sustained α-Gal A expression
lentiviral-based ex vivo gene therapy: Autologous hematopoietic stem cell transduction
Current status: Phase I/II trials ongoing; long-term safety and efficacy data pending
Substrate Reduction Therapy
Research into substrate reduction therapy aims to reduce the production of Gb3 substrate rather than increasing its catabolism[@boyd2013]:
Lucerastat (NCT03425539): Oral glucosylceramide synthase inhibitor; completed Phase III trials but did not meet primary endpoint
Venglustat (NCT02446211): Similar approach; development discontinued for Fabry disease
Pegylated Formulated Enzyme (PEZ)
Pegunigalsidase alfa (PRX-102): Pegylated form of α-Gal A with extended half-life
Dose: 2 mg/kg every 4 weeks
Phase III trials completed; demonstrates potential for less frequent dosing[@gokeralpan2021]
Symptomatic Management
Neuropathic Pain Management
Painful peripheral neuropathy is a hallmark of Fabry disease, resulting from small-fiber neuropathy due to Gb3 accumulation[@polymeropoulos2017].
[Schiffmann R, et al., Enzyme replacement therapy in Fabry disease: A randomized controlled trial. JAMA. 2001 (2001)](https://doi.org/10.1001/jama.285.21.2743)
[Eng CM, et al., A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, pharmacodynamic, and clinical outcomes. Molecular Genetics and Metabolism. 2006 (2006)](https://doi.org/10.1016/j.ymgme.2006.01.009)
[Vedder AC, et al., Comparison of agalsidase alfa and beta in Fabry disease. Journal of Inherited Metabolic Disease. 2007 (2007)](https://doi.org/10.1007/s10545-007-0576-0)
[Germain DP, et al., Migalastat: A review of its use in Fabry disease. BioDrugs. 2019 (2019)](https://doi.org/10.1007/s40259-019-00358-1)
[Hughes DA, et al., Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomized Phase 3 ATTRACT study. Molecular Genetics and Metabolism. 2017 (2017)](https://doi.org/10.1016/j.ymgme.2017.01.016)
[Kohn G, et al., Gene therapy for Fabry disease: Current status and future prospects. Molecular Therapy. 2022 (2022)](https://doi.org/10.1016/j.ymthe.2022.01.015)
[Boyd RE, et al., Substrate reduction therapy for Fabry disease: From bench to bedside. Molecular Genetics and Metabolism. 2013 (2013)](https://doi.org/10.1016/j.ymgme.2013.08.009)
[Goker-Alpan O, et al., Pegunigalsidase alfa: A novel pegylated enzyme replacement therapy for Fabry disease. Molecular Genetics and Metabolism. 2021 (2021)](https://doi.org/10.1016/j.ymgme.2021.01.005)
[Polymeropoulos MH, et al., Neuropathic pain in Fabry disease: Pathophysiology and management. Pain Medicine. 2017 (2017)](https://doi.org/10.1093/pm/pnw321)
[Ortiz A, et al., Fabry disease: Diagnosis and management in the era of enzyme replacement therapy and chaperone therapy. Nature Reviews Nephrology. 2020 (2020)](https://doi.org/10.1038/s41581-020-0270-0)
[Wanner C, et al., European experts' consensus statement on the current and future management of Fabry disease. Nephrology Dialysis Transplantation. 2023 (2023)](https://doi.org/10.1093/ndt/gfad045)